Time to Stop Progesterone Receptor Testing in Breast Cancer Management-Reference-Cited by-同舟云学术

Time to Stop Progesterone Receptor Testing in Breast Cancer Management

Published:2004-05-01 Issue:9 Volume:22 Page:1769-1770
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Olivotto Ivo A.¹,Truong Pauline T.¹,Speers Caroline H.¹,Bernstein Vanessa¹,Allan Sharon J.¹,Kelly Seamus J.²,Lesperance Mary L.³

Affiliation:

1. Radiation Therapy Program, Breast Cancer Outcomes Unit, and Systemic Therapy Program, British Columbia Cancer Agency, Vancouver Island Centre, Victoria, British Columbia, Canada

2. Department of Pathology, Vancouver Island Health Authority, Victoria, British Columbia, Canada

3. Department of Mathematics and Statistics, University of Victoria, Victoria, British Columbia, Canada

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2004.99.251

Reference6 articles.

1. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

2. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

3. Oestrogen and Progesterone Receptors as Prognostic Variables in Hormonally Treated Breast Cancer

4. Prognostic significance of oestrogen and progestogen receptor activities in breast cancer

5. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis;Cancer Causes & Control;2024-02-16

2. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy;Diagnostic Pathology;2024-01-04

3. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy;2023-10-12

4. Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case-cohort analysis;2023-10-09

5. Hormone receptors in breast cancer: An update on the uncommon subtypes;Pathology - Research and Practice;2023-10